Trial reportNature medicine2019
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Trial report in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01856296 (WINTHER), which is not on this map. Cited by 335 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
WINTHER: A Study to Select Rational Therapeutics Based on the Analysis of Matched Tumor and Normal Biopsies in Subjects With Advanced Malignancies
Who cites it
335 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Predicting Immunotherapy Efficacy with Machine Learning in Gastrointestinal Cancers: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.The Cochrane database of systematic reviews · 2025Pooled it
- A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting.The oncologist · 2026Trial
- Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology.Signal transduction and targeted therapy · 2026Trial
- Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.Molecular cancer · 2024Trial
- Trial
- Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.Journal of translational medicine · 2022Trial
- A data-driven cartography of NSCLC vaccine research: Quantifying the paradigm shift toward immuno-oncology combination therapies.Human vaccines & immunotherapeutics · 2026Review
- Deciphering sepsis molecular subtypes using large-scale data to identify subtype-specific drug repurposing.bioRxiv : the preprint server for biology · 2026Article
- Claudin 18.2 Targeting: A Pan-Cancer Perspective.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- SHIVA02 Trial: Using Patients as Their Own Controls to Assess Efficacy of Therapies Based on Molecular Profiling in Patients with Refractory Cancer.Cancer research communications · 2026Article
- Article
- Worldwide Innovative Network Consortium: Building a Common Global Cancer Database.JCO global oncology · 2026Review
- WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.Oncotarget · 2026Article
- A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterogeneity and personalized treatment strategy.Nature communications · 2026Article
- Multi-modal data integration reveals functionally credible predictive biomarkers in ovarian cancer.Genome medicine · 2026Article
- Review
- Functional Precision Oncology Approach Using Nanoliter Droplet Array for Drug Sensitivity Testing in Lung Cancer.Advanced healthcare materials · 2026Article
- SYNTHESIS-Breast: A prospective early-phase trial of a genetic-interaction- focused computational algorithm in advanced metastatic breast cancer.Research square · 2026Article
- GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy.Molecular cancer therapeutics · 2026Article
275 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
25 authors.
Funding
Abstract
Precision medicine focuses on DNA abnormalities, but not all tumors have tractable genomic alterations. The WINTHER trial ( NCT01856296 ) navigated patients to therapy on the basis of fresh biopsy-derived DNA sequencing (arm A; 236 gene panel) or RNA expression (arm B; comparing tumor to normal). The clinical management committee (investigators from five countries) recommended therapies, prioritizing genomic matches; physicians determined the therapy given. Matching scores were calculated post-hoc for each patient, according to drugs received: for DNA, the number of alterations matched divided by the total alteration number; for RNA, expression-matched drug ranks. Overall, 303 patients consented; 107 (35%; 69 in arm A and 38 in arm B) were evaluable for therapy. The median number of previous therapies was three. The most common diagnoses were colon, head and neck, and lung cancers. Among the 107 patients, the rate of stable disease ≥6 months and partial or complete response was 26.2% (arm A: 23.2%; arm B: 31.6% (P = 0.37)). The patient proportion with WINTHER versus previous therapy progression-free survival ratio of >1.5 was 22.4%, which did not meet the pre-specified primary end point. Fewer previous therapies, better performance status and higher matching score correlated with longer progression-free survival (all P < 0.05, multivariate). Our study shows that genomic and transcriptomic profiling are both useful for improving therapy recommendations and patient outcome, and expands personalized cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.